Latest Dopamine agonist Stories
AZ-002 Phase 2a Study in Patients with Epilepsy Planned for Second Half of 2014 MOUNTAIN VIEW, Calif., July 31, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc.
Overall Market Will Increase by a Modest $300 Million From 2008 to 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson's disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents.
Data indicated comparable efficacy and safety for extended release and immediate release formulations of pramipexole SEATTLE, April 29 /PRNewswire/ -- New findings from two double-blind studies investigating the efficacy, safety and tolerability of pramipexole dihydrochloride tablets in an extended release, once-daily formulation, for the treatment of Parkinson's disease (PD), are being presented today at the American Academy of Neurology (AAN) 61st Annual Meeting in Seattle. The first...
By David Douglas NEW YORK (Reuters Health) - A large study confirms that restless legs syndrome (RLS) markedly reduces quality of life and interferes with sleep and that the drug Requip provides significant improvement in symptoms of RLS.
- Emitting flashes of light; glittering.